Biosurgical Agents | Market Insights | Europe | 2021
Although it will be impacted in the short term by the COVID-19 pandemic, the European biosurgical agent market will grow at a modest rate through 2029, primarily driven by growing surgical procedure volumes, rising awareness of the benefits of these products in surgical outcomes, and the introduction of new products with enhanced features and expanded indications. However, the European market continues to be limited by a lack of reimbursement for biosurgical agents, growing concerns over product cost, and reluctance to use products derived from human tissue among some physicians and patients, hindering the pace of market growth.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for biosurgical agents in Europe, with market projections across a 10-year period.
